Dados B3 › NEOE3 × EQTL3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | NEOE3 | EQTL3 | year |
|---|---|---|---|
| ROE | 14.6% | 6.5% | 2025 |
| ROIC | 12.8% | 9.3% | 2025 |
| ROA | 4.4% | 2.2% | 2025 |
| Gross margin | 27.2% | 26.1% | 2025 |
| EBIT margin | 21.4% | 15.6% | 2025 |
| Net margin | 9.6% | 4.8% | 2025 |
| Net debt/EBITDA | 3.39x | 3.90x | 2025 |
| Current ratio | 1.32x | 1.49x | 2025 |
| Revenue growth (1y) | 7.4% | 19.0% | 2025 |
| Revenue growth (5y CAGR) | 10.5% | 23.8% | 2025 |
| Piotroski F-Score | 6/9 | 5/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | NEOE3 | EQTL3 | year |
|---|---|---|---|
| P/E | 7.88x | 32.35x | 2025 |
| P/B | 1.09x | 2.11x | 2025 |
| EV/EBITDA | 6.15x | 8.72x | 2025 |
| FCF yield | 4.0% | -7.6% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:12 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it